Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Phospho-Chk1 (Ser317) Rabbit anti-Human, Polyclonal, Bethyl Laboratories

Rabbit Polyclonal Antibody

Supplier:  Bethyl Laboratories, Inc A304673A

Encompass_Preferred

Catalog No. 50-156-8356


May include imposed supplier surcharges.
Only null left
Add to Cart

Description

Description

The recommended shelf life for this product is 1 year from date of receipt. Application Note: For IHC, epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.

CHK1 (CHEK1) is a kinase that phosphorylates cdc25, an important phosphatase in cell cycle control, particularly for entry into mitosis. CHK1 can also phosphorylate p53 at Ser20 in vitro. Cell cycle events are regulated by the sequential activation and deactivation of cyclin dependent kinases (Cdks) and by proteolysis of cyclins. CHK1 is involved in these processes as regulators of Cdks. CHK1 function as an essential component in the G2 DNA damage checkpoint by phosphorylating Cdc25C in response to DNA damage. Phosphorylation inhibits Cdc25C activity, thereby blocking mitosis. Cdc25A, Cdc25B and Cdc25C protein tyrosine phosphatases function as mitotic activators by dephosphorylating Cdc2 p34 on regulatory tyrosine residues. CHK1 can phosphorylate Wee 1 in vitro, providing evidence that the hyperphosphorylated form of Wee 1, seen in cells delayed by CHK1 overexpression, is due to phosphorylation by CHK1. CHK1 is phosphorylated on Serine 345 (S345) in response to UV, IR and hydroxyurea (HU). CHK1 plays an essential role in the mammalian DNA damage checkpoint, embryonic development and tumor suppression. Further, CHK1 is a key mediator in the DNA damage-induced checkpoint network. CHK1 is an evolutionarily conserved protein kinase that functions to ensure genomic integrity upon genotoxic stress. When the G2 or S checkpoint is abrogated by the inhibition of CHK1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase. Thus, CHK1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient.
Specifications

Specifications

Phospho-Chk1 (Ser317)
Polyclonal
Unconjugated
CHEK1
CHEK1
Rabbit
Antigen affinity chromatography
RUO
1111
4° C
Liquid
Immunohistochemistry, Western Blot
1 mg/ml
phosphate, tris citrate with 0.09% sodium azide; pH 7-8
O14757
CHEK1
Surrounding serine 317
100 μL
Primary
Human
Antibody
IgG
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.